ATL1102

ATL1102

Status

Phase ||

Therapeutic Approach

Reducing Inflammation

ATL1102 is an antisense oligonucleotide designed to inhibit CD49d expressed on T cells implicated in the inflammatory/immune response in Duchenne. Inhibition of CD49d aims to decrease the inflammation that accompanies loss of dystrophin in Duchenne.

Status

A Phase 2A trial is complete.

Sponsor

This program is sponsored by Antisense Therapeutics.

Media Library

JULY 2020

Antisense Therapeutics at the PPMD 2020 Virtual Annual Conference

Pre-recorded content for PPMD's 2020 Virtual Annual Conference On-Demand Library

Join Our Mailing List